Source:http://linkedlifedata.com/resource/pubmed/id/20183607
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
5
|
pubmed:dateCreated |
2010-2-25
|
pubmed:abstractText |
Metalation of 6-methyl-9-(tetrahydro-2H-pyran-2-yl)purine (10) with lithiating agents of varying basicities such as n-BuLi and LiHMDS in THF at -78 degrees C resulted in metalation at both of the 6-CH(3) moiety and the 8-CH position, irrespective of the molar equivalence of the base. On the other hand, a regioselective metalation at the 6-CH(3) moiety of 10 was observed with NaHMDS or KHMDS, under similar conditions. Treatment of the potassium salts of 10 and of the protected riboside derivative 6-methyl-9-(beta-D-2,3,5-tri-O-tert-butyldimethylsilylribofuranosyl)purine (22) with N-fluorobenzenesulfonamide (NFSI) at -78 degrees C gave the corresponding 6-fluoromethylpurine derivatives 11 and 23, respectively, in good yields. Deprotection of 11 and 23 under standard conditions gave 6-fluoromethylpurine (6-FMeP, 3) and 6-fluoromethyl-9-(beta-D-ribofuranosyl)purine (6-FMePR, 4), respectively, in high yield. Both 3 and 4 demonstrated cytotoxic activity against CCRF-CEM cells in culture. 6-FMePR is a good substrate for E. coli purine nucleoside phosphorylase (E. coli PNP) with a comparable substrate activity to that of the parent nucleoside, 6-methyl-9-(beta-D-ribofuranosyl)purine (6-MePR, 21). The cytotoxic activity of 6-FMeP along with the substrate activity of 6-FMePR with E. coli PNP meet the fundamental requirements for using 6-FMeP as a potential toxin in PNP/prodrug based cancer gene therapy.
|
pubmed:grant | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
May
|
pubmed:issn |
1532-2335
|
pubmed:author | |
pubmed:issnType |
Electronic
|
pubmed:volume |
28
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
642-56
|
pubmed:meshHeading |
pubmed-meshheading:20183607-Antineoplastic Agents,
pubmed-meshheading:20183607-Cell Line, Tumor,
pubmed-meshheading:20183607-Cell Proliferation,
pubmed-meshheading:20183607-Escherichia coli,
pubmed-meshheading:20183607-Gene Therapy,
pubmed-meshheading:20183607-Halogenation,
pubmed-meshheading:20183607-Humans,
pubmed-meshheading:20183607-Neoplasms,
pubmed-meshheading:20183607-Purine-Nucleoside Phosphorylase,
pubmed-meshheading:20183607-Purines
|
pubmed:year |
2009
|
pubmed:articleTitle |
Regioselective metalation of 6-methylpurines: synthesis of fluoromethyl purines and related nucleosides for suicide gene therapy of cancer.
|
pubmed:affiliation |
Southern Research Institute, Drug Discovery Division, Birmingham, Alabama, USA.
|
pubmed:publicationType |
Journal Article,
Research Support, N.I.H., Extramural
|